The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.
News & Analysis: Lannett
Forty-four states have brought a lawsuit against the industry.
Quarterly operating results were pretty good, but the business disclosed that it may face a lawsuit along with other makers of generic drugs.
LCI earnings call for the period ending March 31, 2019.
LCI earnings call for the period ending December 31, 2018.
Investors sent shares soaring yesterday, but the future is still chock full of uncertainty for the generic drug distributor.
The hits keep coming for this generic-drug manufacturer.
These three stocks were under pressure despite the broader market's gains. Here's what investors need to know.
Shares get cut in half after the company announces the loss of a key customer. Here's what investors need to know.
A cancer-drug developer, generic-drug manufacturer, and medical device kingpin may be just what the doctor ordered.